Side-effects of carbetocin to prevent postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials

Wen Ai | Yanfei Zeng | Yubo Ma | Li Liu | Dazhi Fan | Song Wu | Yinghui Zhang

1Department of Obstetrics and Gynecology, Foshan Chancheng Central Hospital, Foshan, Guangdong, China
2Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
3Department of Library, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
4Foshan Institute of Fetal Medicine, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, Guangdong, China
5School of Integrated Traditional and Western Medicine, Anhui University of Chinese Medicine, Hefei, Anhui, China

Correspondence
Yinghui Zhang or Dazhi Fan, Department of Obstetrics and Gynecology, Foshan Chancheng Central Hospital, 3 Sanyounan Road, Foshan, Guangdong, 528000, China.
Emails: 13542511669@163.com (Y. Z.); fandazhigw@163.com (D. F.)

Abstract
Postpartum hemorrhage (PPH) increases the risk of maternal death worldwide. Heat-stable carbetocin, a long-acting oxytocin analog, is a newer uterotonic agent. Clinicians do not fully understand its side-effects, particularly the unanticipated side-effects. The aim of this study is to investigate the side-effects of carbetocin to PPH. The Cochrane Library, Web of Science, PubMed, Elsevier ScienceDirect, Embase, and ClinicalTrials.gov were searched from the inception to September 2020. Randomized controlled trials (RCTs) that considered pregnant women who received carbetocin before delivery and provided at least one adverse event were included. Statistical analysis included random or fixed-effect meta-analyses using relative risk. Stratified analyses and sensitivity analyses were also performed. Begger’s and Egger’s test and funnel plots were used to assess the publication bias. Seventeen RCTs involving 32,702 women were included, and all these studies ranked as medium- to high-quality. Twenty-four side-effects were reported. The use of carbetocin had a lower risk of vomiting in intravenously (0.53, 0.30 to 0.93) and cesarean birth (0.51, 0.32 to 0.81) women, and had a slightly higher risk of diarrhea (8.00, 1.02 to 62.79) compared with oxytocin intervention. No significant difference was found among other side-effects. Evidence from our systematic review and meta-analysis of 17 RCTs suggested that the risk of vomiting decreased with carbetocin use in the prevention of PPH after delivery.

KEYWORDS
carbetocin, meta-analysis, postpartum hemorrhage, side-effects, systematic review

Abbreviations: CIs, confidence intervals; PPH, postpartum hemorrhage; RCTs, randomized controlled trials; RR, relative risk.

Wen Ai and Yanfei Zeng contributed equally to this article.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
1 | INTRODUCTION

Postpartum hemorrhage (PPH) caused a significant number of maternal deaths worldwide. About 27.1% of all maternal deaths were caused by hemorrhage, and these data can reach 36.9% in most low-income countries and regions. It has already been confirmed that prophylactic administration of uterotonic agents is the most important component in terms of reducing the risk of PPH and preventing the irreversible functional consequences in the stage of labour.

Oxytocin, a short half-life uterotonic agent, is recommended by the World Health Organization (WHO) as the first line for the prevention and treatment of PPH in 2012. However, it is sensitive to heat and requires cold storage and transport in usage. The active ingredient and purity are mostly affected in low-resource settings where the cold chain is not commonly available. Because of its heat sensitivity, it does not possess satisfactory real-world efficacy, particularly in hot low- and middle-income countries and regions. Meanwhile, the short half-life required frequently or continuously repeated administration.

Heat-stable carbetocin, a long-acting oxytocin analog, is a newer uterotonic agent. Its effects of uterine contractions can start within two minutes, and the rhythmic contractions can last for 60 to 120 minutes in intravenous and intramuscular injection, respectively. What is important is that it has high thermal stability, and it can be transported and stored at normal temperature and even in hot and humid environments without compromising quality. The heat-stability data showed that it maintained for a minimum of 36 months at 30°C and 75% relative humidity and at extreme temperatures, such as 50°C, for three months. Hence, it would be advantageous and even a significant breakthrough for maternal health in hot environments lacking cold chain routes to use carbetocin. Recently, a multicenter clinical trial, including 23 hospitals in 10 countries, indicated that the intramuscular administration of 100 ug of heat-stable carbetocin was noninferior to the administration of 10 IU oxytocin for the prevention of PPH after vaginal birth. Meanwhile, systematic reviews and meta-analysis demonstrated that carbetocin significantly reduced postpartum blood loss, additional uterotonic, and transfusion. The use of carbetocin is recommended for the prevention of PPH for all births by WHO, particularly in settings where oxytocin is unavailable or its quality cannot be guaranteed.

Side-effects were also an important concern when choosing uterotonic agents. Although carbetocin seems to be an ideal agent compared to other uterotonic agents, some side-effects, such as vomiting, nausea, and dysarteriotony, are still concerned. There are many trials of carbetocin use to prevent PPH, and side-effects are always as secondary outcomes in these trials. Clinicians do not fully understand the side-effects of carbetocin to PPH, particularly the unanticipated ones. There seems to be a gap to detailed presentation of the side-effects of carbetocin. Therefore, this study aims to assess the side-effects of prophylactic carbetocin to PPH among the previous randomized clinical trials.

2 | MATERIALS AND METHODS

This systematic review was pre-registered online in the PROSPERO registry (CRD42019134522). The perform of the current study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The ethical approval was not required for this study.

2.1 | Search strategy

A systematic search of the Cochrane Library, Web of Science, PubMed, Elsevier ScienceDirect, ClinicalTrials.gov, and Embase was conducted from the earliest publication date available through May 31, 2019. The search was updated on September 1, 2020. The MeSH search terms including Carbetocin, Postpartum Hemorrhage, and Randomized Clinical Trials were used and were listed in detail in Appendix 1. There is no language restriction. A manually snowball search strategy was also used to identify additional studies from the reference lists of retrieved studies and relevant reviews.

2.2 | Inclusion and exclusion criteria

Studies were considered if the following criteria were met: 1) randomized controlled trials (RCTs) design, 2) pregnant women received the prophylactic carbetocin before delivery, 3) compared carbetocin with oxytocin or placebo interventions, and 4) provided the frequency of at least one side-effect. Cluster- or quasi-RCTs, ongoing trials, cross-sectional studies, case series, abstracts without full text, or studies without sufficient data were excluded.

2.3 | Study selection and data extraction

Two authors (Wen Ai and Dazhi Fan) independently identified eligible articles on title and abstract first, and then on the full text. The data extraction was also independently performed by the same authors using a prespecified Excel form, and the extracted variables from each study included study and participant characteristics (first author, year of publication, region, trial registration number, funding source, risk of PPH, and mode of delivery), arms and treatment regimens (dose and route), and the type and frequency of side-effects. Disagreement between authors was solved by discussion between the two authors. Meanwhile, we also entered the data into the EpiDate software to check the accuracy.

2.4 | Risk of bias assessment

Using the Cochrane Handbook, two authors (Yanfei Zeng and YuBo Ma) independently assessed the quality of the included studies. Evaluation criteria included the following major domains: randomization, implementation of blind, data reporting, and other bias, such as funding source, and potential conflicts of interest.
Data analyses

The assessment was the relative risk (RR) with 95% confidence intervals (CIs) comparing the frequency of side-effects between carbetocin and control groups, which was calculated using frequentist pairwise meta-analysis. Forest plots were used to present the results of RR and 95% CIs. Heterogeneity across studies was assessed using Tau², I², and Chi² statistics. The selected effect models, fixed or random, were based on the heterogeneity result.

For all side-effects, if they were provided by ten or more trials, we stratified analyses by the route of carbetocin administration (intravenously versus intramuscularly), mode of delivery (vaginal versus cesarean birth), prior risk of PPH (high, low or none), trial register (yes or no), funding source (company, researcher, or none), and control-intervention ways to identify the main sources of heterogeneity between trials. To assess the dose effect, a sensitivity analysis was performed to exclude the trial in which the carbetocin dose was not 100 micrograms. To assess the publication bias, the Begger and Egger tests were used. Data analysis and graphing were conducted using the R software, the Review Manager software, and Microsoft Excel.

3 | RESULTS

3.1 | Study identification and characteristics

We first identified 221 potentially eligible articles, and 136 articles were scrutinized for the full text. Ultimately, a total of 17 RCTs involving 32,702 women were included (Figure 1). Two articles...
| First author         | Publish Year | Trial Phase | Trial No.                                      | Funded | Country                      | Risk for PPH | Delivery Mode | Interventions (sample size; dose; adm) | Side effects                  |
|----------------------|--------------|-------------|-----------------------------------------------|--------|------------------------------|--------------|--------------|----------------------------------------|-------------------------------|
| Mannaerts D\(^1\)   | 2018         | NA          | ISRCTN 95504420                               | NA     | Belgium                      | L            | CS           | Carbetocin (32; 100 ug, i.v.) vs. Oxytocin (26; 20 i.u, i.v.) | Nausea; Flushing; Hypotension; Vomiting |
| Taheripanah R\(^2\)  | 2018         | II          | NCT02079558                                   |        | Iran                         | H            | CS           | Carbetocin (110; 100 ug, i.v.) vs. Oxytocin (110; 30 i.u, i.v.) | Vomiting; Headache; Nausea; Tremor; Dizziness; Pruritus |
| Widmer M\(^3\)       | 2018         | III         | ACTRN12614000870651; 2014-004445-26; CTRI/2016/05/006969 |        | Argentine; Egypt; India; Kenya; Nigeria; Singapore; South Africa; Thailand; Uganda; the United Kingdom | L            | VD           | Carbetocin (14754; 100 ug, i.m.) vs. Oxytocin (14743; 10 i.u, i.m.) | Chest pain; Flushing; Abdominal pain; Vomiting |
| El Behery MM\(^4\)   | 2016         | NA          | NA                                            | NA     | Egypt                        | H            | CS           | Carbetocin (90; 100 ug, i.v.) vs. Oxytocin (90; 20 i.u, i.v.) | Headache; Nausea; Vomiting; Sweating; Palpitations; Fever |
| Maged AM\(^5\)       | 2016         | NA          | NA                                            | NA     | Egypt                        | H            | VD           | Carbetocin (100; 100 ug, i.m.) vs. Oxytocin (100; 100 ug, i.m.) | Nausea; Vomiting; Tachycardia; Flushing; Dizziness; Headache; Shivering; Anemia; Metallic taste; Dyspnea; Palpitations; Itching |

(Continues)
| First author       | Publish Year | Trial Phase | Trial No.            | Funded             | Country       | Risk for PPH | Delivery Mode | Interventions (sample size; dose; adm)                  | Side effects                                                                 |
|-------------------|--------------|-------------|----------------------|--------------------|---------------|--------------|---------------|----------------------------------------------------------|-----------------------------------------------------------------------------|
| Maged AM          | 2016         | III         | NCT02304055          | Cairo University   | Egypt         | H            | VD            | Carbetocin (50; 100 ug, i.v.) vs. Oxytocin (50; 5 iu, i.v.) | Nausea; Vomiting; Tachycardia; Flushing; Dizziness; Headache; Shivering; Metallic taste; Dyspnea; Palpitations; Itching |
| Razali N          | 2016         | NA          | ISRCTN18976822       | the University of Malaya | Malaysia      | L            | CS            | Carbetocin (276; 100 ug, i.v.) vs. Oxytocin (271; 10 iu, i.v.) | Arrhythmias                                                                |
| Sunil Kumar KS    | 2016         | NA          | NA                   | NA                 | India         | L            | VD            | Carbetocin (100; 125 ug, i.m.) vs Oxytocin (100; 10 iu, i.m.) | Nausea; Vomiting; Shivering; Diarrhea; Fever                                |
| Ortiz-Gomez JR    | 2013         | NA          | NA                   | NA                 | Spain         | NA           | CS            | Carbetocin (52; 100 ug, i.v.) vs Oxytocin (52, 52; 1 iu, 20 iu, i.v.) | Nausea; Vomiting; Nausea; Tremor; Headache; Chest pain; |
| Rosseland LA      | 2013         | IV          | NCT00977769          | Ferring Pharmaceutical | Norway        | H            | CS            | Carbetocin (25; 100 ug, i.v.) vs. Oxytocin (26; 5 iu, i.v.) vs. placebo | Metallic taste; Xerostomia; Nasal congestion; Headache; Flushing; Palpitations; Shortness of breath; Chest pain; Feeling of warmth; |
| Moertl MG         | 2011         | NA          | 2007–005498–78; NCT01277978 | Medical University of Graz | Austria       | H            | CS            | Carbetocin (28; 100 ug, i.v.) vs. Oxytocin (28; 5 iu, i.v.) | Nausea; Flushing; Headache; Tachycardia; Shortness of breath; Feeling warm; |

(Continues)
| First author | Publish Year | Trial Phase | Trial No. | Funded | Country | Risk for PPH | Delivery Mode | Interventions (sample size; dose; adm) | Side effects |
|--------------|--------------|-------------|-----------|--------|---------|--------------|--------------|--------------------------------------|--------------|
| Reyes OA    | 2011         | NA          | NA        | NA     | Panama | H            | VD           | Carbetocin (26; 100 ug, iv.) vs. Oxytocin (29; 20 iu, i.v.) | Headaches; Palpitations; Fever; Nausea; Vomiting; Hot sensation; Flushing; Malaise |
| Attilakos G  | 2010         | NA          | 2005–002812–94 | NA     | UK      | High        | CS           | Carbetocin (188; 100 ug, i.v.) vs. Oxytocin (189; 5 iu, i.v.) | Nausea; Vomiting; Headache; Tachycardia; Metallic taste; Backache; Abdominal pain; Arm pain; Trigeminy; Flushed; Shortness of breath; Wheezing; Tremors; Hypotension; Sweating; Tightness throat; ST depression; Blurred vision; |
| Borruto F    | 2009         | NA          | NA        | NA     | Italy   | H            | CS           | Carbetocin (52; 100 ug, i.v.) vs. Oxytocin (52; 10 iu, i.v.) | Anemia; Arrhythmias; Abdominal pain; Nausea; Vomiting; Metallic taste; Heat sensation; Back pain; Headache; Tremor; Dizziness; Difficulty in breathing; Dyspnea; Chest pain; Pruritus; Flushing; Hypotension; |
| First author | Publish Year | Trial Phase | Trial No. | Funded | Country | Risk for PPH | Delivery Mode | Interventions (sample size; dose; adm) | Side effects |
|--------------|--------------|-------------|-----------|--------|---------|-------------|--------------|---------------------------------------|--------------|
| Boucher M²⁸  | 2004         | NA          | NA        | NA     | Canada  | H           | VD           | Carbetocin (83; 100 ug, i.m.) vs. Oxytocin (77; 10 iu, i.v.) | Headache; Chills; Abdominal pain; Dizziness; Tremor; Vasodilatation; Leukocytosis; Nausea; Vomiting; Pruritus |
| Dansereau J²⁷ | 1999         | NA          | NA        | NA     | Canada  | H           | CS           | Carbetocin (329; 100 ug, i.v.) vs. Oxytocin (330; 25 iu, i.v.) | Abdominal pain; Back pain; Headache; Nausea; Metallic taste; Flushing; Sweating; Tremors; Vomiting; Feeling of warmth; |
| Boucher M²⁶  | 1998         | NA          | NA        | NA     | Canada  | NA          | CS           | Carbetocin (29; 100 ug, i.v.) vs. Oxytocin (28; 10 iu, i.v.) | Vomiting; Nausea; Dizziness; Pruritus; Headache; Shortness of breath; Chills |

Abbreviations: CS, cesarean section; H, high risk for PPH; HL, high and low risk for PPH; L, low risk for PPH; NA, none; PPH, postpartum hemorrhage; VD, vaginal birth.
contained three arms, respectively. They were published from 1998 to 2018. The median size was 160 participants with the interquartile range of 67 to 299. Of the included 17 studies, 11 articles were designed for women following cesarean deliveries and six were for women undergoing vaginal deliveries. Ten out of 17 articles recruited women with high risk factors for PPH and five recruited women with low risk factors. The risk factor is not specified in two articles. All of the articles compared the use of carbetocin with oxytocin, and only one article contained one trial of carbetocin versus placebo.

Except for Sunil Kumar KS’s article (125 ug), all articles performed a standard dose of 100 ug carbetocin. The articles were conducted in various countries. The most articles were conducted from the Egypt (n = 3) and Canada (n = 3), followed by Austria, Belgium, India, Iran, Italy, Malaysia, Norway, Panama, Spain, and UK (n = 1 each); and one article involved 23 hospitals in 10 countries. Eight articles were pre-registered in the Web-based registry of clinical trials, such as ClinicalTrials.gov. Four articles were funded by pharmaceutical company, four articles were funded by organizations, university, or hospital, and nine articles did not disclose funding sources. (Table 1).

A total of 24 side-effects were reported in this study. Most of articles reported vomiting (14 articles), nausea (14), headache (13), and flushing (10) as side-effects of carbetocin. Less than ten articles reported side-effects included shivering (9), heart disorders (9), dizziness (8), dyspnea (7), pruritus (6), metallic taste (6), abdominal pain (5), fever (4), chest pain (4), feeling of warmth (4), hypotension (3), backache (3), sweating (3), chills (2), anemia (2), xerostomia (1), serious adverse event (1), arm pain (1), diarrhea (1), and leukocytosis (1).

### 3.2 Risk of bias

The quality of the included articles varied. In each of the domain, most of the articles were rated with low or unclear risk of bias. High risk of bias was mostly attributed to incomplete outcome data and other bias, such as granting by the pharmaceutical company and the failure to declare potential conflicts of interest. Meanwhile, performance and detection bias existed in one article. In general, the quality was good, with five high-quality articles, twelve moderate quality articles, and none of the articles was classified as low quality (Figures 2, 3).

### 3.3 Quantitative analysis

The use of carbetocin had a slightly higher risk of diarrhea (8.00; 1.02–62.79) compared with oxytocin intervention. In subgroup analysis, the use of carbetocin had a lower risk of vomiting in intravenously group (0.53; 0.30–0.93) and in cesarean birth women (0.51; 0.32–0.81). In addition, carbetocin use had a lower risk of vomiting (0.32; 0.18–0.55) in no fund. Except for above reporting, other side-effects and subgroup analysis were not found different between the two interventions (Figure 4; Appendix 2).

### 3.4 Sensitivity analysis and publication bias

Sensitivity analysis by excluding a dose of 125 ug carbetocin trial showed that the results were not substantial influenced, and they were just slight changes. Funnel plots and Begg’s and Egger’s tests found no significant publication bias.

### 4 Discussion

In this systematic review and meta-analysis, which included 17 RCT studies covering 32,702 women, we found that vomiting, nausea, headache, and flushing are the most frequently reported side-effects of carbetocin to PPH. The risk of vomiting decreased with
Fewer clinical trials have focused on the side-effects of carbetocin to prevent PPH. Mannaerts D et al.16 have compared the adverse effects between carbetocin and oxytocin in their trial. They found the incidence of nausea was lower after carbetocin, but there was no statistical difference. A previous review, only included several studies, also showed that carbetocin is associated with fewer adverse effects.10 Furthermore, our study demonstrated that the administration of carbetocin in delivery is associated with the lower incidence of vomiting. We therefore suggested that carbetocin might be considered as an appropriate choice for pregnant women with vomiting intolerance for the prevention of PPH.

Studies suggested that carbetocin is superior in terms of additional uterotonics when compared with other uterotonic agent at cesarean delivery.25,28 Meanwhile, in a prospective double-blinded randomized study, Maged AM et al found that carbetocin is a better alternative to oxytocin in prevention of PPH after vaginal delivery in women with at least two risk factors of atonic PPH.19 In the subgroup analysis, we found carbetocin had a lower risk of vomiting at cesarean delivery when compared with oxytocin intervention. In addition, this analysis also demonstrated that there is a reduced risk of vomiting with carbetocin intravenously use. Considering the effects and side effects, carbetocin should be a good choice at cesarean delivery, particularly in intravenously use.

Compared with oxytocin, carbetocin has a longer half-life, and both amplitude and frequency of contractions are prolonged when administered postpartum.29 Carbetocin has an efficacy and safety profile very similar to oxytocin.30 A Cochrane review showed that carbetocin significantly reduces the need for additional uterotonics compared to oxytocin.10 However, the cost of carbetocin is prohibitively expensive. The absolute cost of carbetocin is several times higher than oxytocin.31 Some researchers have even found there is no economic benefit with the use of carbetocin for women from the point of view of health system.32,33

While many systematic reviews have been published on the carbetocin use, these studies mostly discuss the efficacy aspect of carbetocin in the prevention of PPH. Our study, however, is the first review amalgamating the evidence from available RCT studies with a focus on the safety aspect of carbetocin. Our review benefits from a comprehensive search strategy which captures 17 trials involving 32,072 women and 24 most common side-effects occurring due to carbetocin. The large sample size achieved high precision results, particularly in the rare side-effects. Moreover, the review was based on a prospective protocol which had been pre-registered on PROSPERO registry. Furthermore, the meta-analyses were designed carefully with strict subgroup analysis of participants and carbetocin administration characteristics. Meanwhile, sensitivity analyses demonstrated that the findings were robust.

However, some limitations in this review or in the included studies should be noted. Many of the included side-effects were small or none in size, presenting a possibility to generate spurious associations. The time span of the included RCTs was more than 20 years, involving more than a dozen developed or developing countries and regions. Some symptoms and signs, such as flushing, feeling of

FIGURE 3 Results of the risk of bias for 17 included randomized controlled trials. Green means low risk; yellow means unclear risk; red means high risk

carbetocin use in intravenously and cesarean birth women in the prevention of PPH after delivery. The result was based on medium-to high-quality evidence.
warmth, and tremors, may be defined inconsistently in different trials. This may increase the risk of merging apple and orange.

5 | CONCLUSION

The overall results of our systematic review and meta-analysis study may raise concerns about the potential side-effects of uterotonic agents use for preventing postpartum hemorrhage. It may help clinicians better understand the side-effects, particularly the unanticipated side-effects, of carbetocin use during labor and delivery. These results provide insights toward optimizing clinical decision-making strategies, which should consider the potential benefits of using carbetocin to prevent PPH in parts of the world where a lack of cold chain transported and stored.

ACKNOWLEDGMENTS

We appreciate the efforts of all the researchers whose articles were included in this study. In addition, this work was not supported by any funding.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS

DF and YZ participated in the design and coordination of the study. WA conceived the study and drafted the manuscript. YZ, YM, and LL searched for the studies, collected, and analyzed the data. DF participated in the design of this study and edited the manuscript. DF, SW, YZ, and YM did the data management and analyzed the data. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

The data used to support the findings of this study are included within the article.

REFERENCES

1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014;2(6):e323-e333.
2. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Geneva; 2018.
3. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva; 2012.
4. Torloni MR, Gomes Freitas C, Kartoglu UH, Metin Gulmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG: an international journal of obstetrics and gynaecology. 2016;123(13):2076-2086.
5. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D1082.
6. Kim S, Thiessen PA, Bolton EE, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016;44(D1):D1202-D1213.
7. Malm M, Madsen I, Kjellstrom J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. J Peptide Sci: an official publication of the European Peptide Society. 2018;24(6):e3082.
8. Widmer M, Piaggio G, Nguyen TMH, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med. 2018;379(8):743-752.
9. Voon HY, Suharjono NH, Sfaffie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-analysis of randomized controlled trials in cesarean deliveries. Taiwanese J Obstetrics & Gynecol. 2018;57(3):332-339.
10. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. The Cochrane Database Systematic Reviews. 2012;4:CD005457.
11. Higgins JPT, Se G. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011). Cochrane Collaboration website. http://training.cochrane.org/handbook.2011. Accessed November 22, 2017.
12. Rosseland LA, Hauge TH, Grindheim G, Stubhaug A, Langesaeter E. Changes in blood pressure and cardiac output during cesarean delivery: the effects of oxytocin and carbetocin compared with placebo. Anesthesiology. 2013;119(3):541-551.

13. Ortiz-Gomez JR, Morillas-Ramirez F, Fornet-Ruiz I, Palacio-Abizanda FJ, Bermejo-Albares L. Clinical and pharmacological study of the efficacy of carbetocin in elective caesareans compared to low and usual doses of oxytocin. Rev Esp Anestesiol Reanim. 2013;60(1):7-15.

14. Boucher M, Horbay GL, Griffin P, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol: official journal of the California Perinatal Association. 1998;18(3):202-207.

15. Sunil Kumar KS, Shyam S, Batakurki P. Carboprost Versus Oxytocin for Active Management of Third Stage of Labor: A Prospective Randomized Control Study. J Obstetrics Gynaecol India. 2016;66(Suppl 1):229-234.

16. Mannaaerts D, Van der Veeken L, Coppejans H, Jacquemyn Y. Adverse Effects of Carbetocin versus Oxytocin in the Prevention of Postpartum Haemorrhage after Caesarean Section: A Randomized Controlled Trial. J Pregnancy. 2018;2018:1374150.

17. Taheripanah R, Shoman A, Karimzadeh MA, Zamanian M, Malih N. Efficacy of oxytocin versus carbetocin in prevention of postpartum hemorrhage after cesarean section under general anesthesia: a prospective randomized clinical trial. Journal of Maternal-Fetal & Neonatal Medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2018;31(21):2807-2812.

18. El Behery MM, El Sayed GA, El Hameed GA, Soliman BS, Abdelsalam WA, Bahaa A. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in obese nulliparous women undergoing emergency cesarean delivery. J Maternal-Fetal & Neonatal Medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(8):1257-1260.

19. Maged AM, Hassan AM, Shehata NA. Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. J Maternal-Fetal & Neonatal Medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(4):532-536.

20. Maged AM, Hassan AM, Shehata NA. Carbetocin versus oxytocin in the management of atomic post partum haemorrhage (PPH) after vaginal delivery: a randomised controlled trial. Arch Gynecol Obstet. 2016;293(5):993-999.

21. Razali N, Md Latar IL, Chan YK, Omar SZ, Tan PC. Carbetocin compared to oxytocin in emergency cesarean section: a randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016;198:35-39.

22. Moertl MG, Friedrich S, Krasch J, Wadsack C, Lang U, Schlembach D. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. BJOG: an international journal of obstetrics and gynaecology. 2011;118(11):1349-1356.

23. Reyes OA, Gonzalez GM. Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: A Double-Blind Randomized Controlled Trial. J Obstetrics Gynaecol Canada. 2011;33(11):1099-1104.

24. Attilakos G, Psaroudakis D, Ash J, et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG: an international journal of obstetrics and gynaecology. 2010;117(8):929-936.

25. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009;280(5):707-712.

26. Boucher M, Nimrod CA, Tawagi GF, Meeker TA, Rennicks White RE, Varin J. Comparison of Carbetocin and Oxytocin for the Prevention of Postpartum Hemorrhage Following Vaginal Delivery: A Double-Blind Randomized Trial. J Obstet Gynaecol Canada. 2004;26(5):481-488.

27. Dansereau J, Joshi AK, Helewra ME, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol. 1999;180(3 Pt 1):670-676.

28. Gallos ID, Carbetocin CA. Worth the extra expense? Best Practice & Res Clinical Obstet & Gynaecol. 2019.

29. Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992;52(1):60-67.

30. Gallos ID, Williams HM, Price MJ, et al. Uterotonin agents for preventing postpartum haemorrhage: a network meta-analysis. The Cochrane Database of Systematic Reviews. 2018;4:CD011689.

31. Voon HY, Shafie AA, Bujang MA, Suharjono HN. Cost effectiveness analysis of carbetocin during cesarean section in a high volume maternity unit. J Obstet Gynaecol Res. 2018;44(1):109-116.

32. Gil-Rojas Y, Lasalvá P, Hernández F, Castaneda-Cardona C, Rosselli D. Cost-effectiveness of Carbetocin versus Oxytocin for Prevention of Postpartum Hemorrhage Resulting from Uterine Atony in Women at high-risk for bleeding in Colombia. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia. 2018;40(5):242-250.

33. Higgins L, Mechery J, Tomlinson AJ. Does carbetocin for prevention of postpartum haemorrhage at caesarean section provide clinical or financial benefit compared with oxytocin? J Obstet Gynaecol: the journal of the Institute of Obstetrics and Gynaecology. 2011;31(8):732-739.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Ai W, Zeng Y, Ma Y, et al. Side-effects of carbetocin to prevent postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res Perspect. 2021;9:e00745. https://doi.org/10.1002/prp2.745